Sign in

    Steven Etoch

    Senior Associate and equity analyst at Stephens Inc.

    Steven Etoch is a Senior Associate and equity analyst at Stephens Inc., specializing in the life science tools and pharma services sector. He actively covers companies such as STERIS plc, Stevanato Group SpA, and Lifecore Biomedical Inc., and has participated in recent earnings calls for these firms; performance metrics indicate an average return of approximately -1.1% and a low success rate based on public analyst rankings. Etoch began his career with Stephens in 2018, following his graduation with a Master of Finance from Southern Methodist University Cox School of Business and a B.S.B.A. in Finance with minors in Biology and Management from the University of Arkansas. Professionally, he holds FINRA Series 63 and Series 65 licenses and is registered to provide investment advice in Texas.

    Steven Etoch's questions to STERIS (STE) leadership

    Steven Etoch's questions to STERIS (STE) leadership • Q4 2025

    Question

    Steven Etoch requested more detail on the customer dynamics within the AST segment that support the 6-7% growth outlook and asked if there have been any notable changes in client behavior in Life Sciences or AST due to the current macro environment.

    Answer

    President and CEO Daniel Carestio explained the AST outlook reflects a conservative approach, factoring in month-to-month volume variability and a cautious view on the bioprocessing recovery timeline. He noted that while discussions with clients about the macro environment are ongoing, there have been no concrete changes in behavior to report.

    Ask Fintool Equity Research AI

    Steven Etoch's questions to Stevanato Group S.p.A. (STVN) leadership

    Steven Etoch's questions to Stevanato Group S.p.A. (STVN) leadership • Q1 2025

    Question

    Steven Etoch asked if there was a shift in customer ordering patterns due to tariffs and requested a breakdown of the margin improvement drivers between EZ-fill recovery and the new facility ramp-ups.

    Answer

    CEO Franco Stevanato confirmed that customer ordering patterns have not changed due to tariffs; the recent increase is related to the end of destocking. CFO Marco Dal Lago clarified that the primary driver of margin improvement was the operational scaling of the Latina and Fishers facilities, followed by the favorable product mix from high-value solutions.

    Ask Fintool Equity Research AI

    Steven Etoch's questions to LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) leadership

    Steven Etoch's questions to LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) leadership • Q1 2025

    Question

    Steven Etoch asked CFO Ryan Lake about his near-term focus areas, opportunities for margin improvement beyond recent announcements, and whether the company is appropriately sized for sustainable growth.

    Answer

    Ryan Lake, CFO, stated his initial focus has been on the finance team, SEC filings, and the recent capital raise. He provided detailed financial cadence expectations, projecting revenue to be split 40/60 between the first and second halves of the year, with gross profit split 30/70. Lake noted that while OpEx will be similar to the prior year, it will be front-loaded, and he anticipates mid-single-digit million-dollar cost savings in the second half, leading to adjusted EBITDA being heavily weighted to H2.

    Ask Fintool Equity Research AI